Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 20 , ISSUE 7 ( 2016 ) > List of Articles

CASE REPORT

Systemic thrombolysis with recombinant tissue plasminogen activator for acute life-threatening Blalock-Taussig shunt obstruction

Franco Diaz, William C. Sasser, Mark A. Law, Jeffrey A. Alten

Keywords : Congenital heart disease, fibrinolysis, shunt thrombosis, tissue plasminogen activator

Citation Information : Diaz F, Sasser WC, Law MA, Alten JA. Systemic thrombolysis with recombinant tissue plasminogen activator for acute life-threatening Blalock-Taussig shunt obstruction. Indian J Crit Care Med 2016; 20 (7):425-427.

DOI: 10.4103/0972-5229.186248

License: CC BY-ND 3.0

Published Online: 01-07-2016

Copyright Statement:  Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Modified Blalock-Taussig shunt (mBTS) obstruction can be life-threatening, especially when it represents the only source of pulmonary blood flow. Current therapeutic options to reverse obstruction include surgical shunt revision/replacement, interventional endovascular procedures including balloon angioplasty and/or stent placement, and a combination of local and systemic thrombolytic therapy. We report two cases of acute mBTS thrombosis successfully treated with systemic recombinant tissue plasminogen activator in infants convalescing after cardiac surgery when the clinical status and resources precluded traditionally described rescue therapies.


PDF Share
  1. Moszura T, Zubrzycka M, Michalak KW, Rewers B, Dryzek P, Moll JJ, et al. Acute and late obstruction of a modified Blalock-Taussig shunt: A two-center experience in different catheter-based methods of treatment. Interact Cardiovasc Thorac Surg 2010;10:727-31.
  2. Kogon B, Villari C, Shah N, Kirshbom P, Kanter K, Kim D, et al. Occlusion of the modified Blalock-Taussig shunt: Unique methods of treatment and review of catheter-based intervention. Congenit Heart Dis 2007;2:185-90.
  3. Manco-Johnson MJ, Grabowski EF, Hellgreen M, Kemahli AS, Massicotte MP, Muntean W, et al. Recommendations for tPA thrombolysis in children. On behalf of the scientific subcommittee on perinatal and pediatric thrombosis of the scientific and standardization committee of the international society of thrombosis and haemostasis. Thromb Haemost 2002;88:157-8.
  4. Monagle P, Chan A, Goldenberg NA, Ichord RN, Joyrneycake JM, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9 th Edition). Chest 2012;133:887S-968S.
  5. Santiago MJ, Lopez-Herce J, Del Castillo DB. Thrombolytic therapy using a low dose of tissue plasminogen activator in children. Catheter Cardiovasc Interv 2014;83:339-40.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.